Toronto-Dominion Bank Stock
€97.41
Your prediction
Financial data and news for TD
sharewise wants to provide you with the best news and tools for TD, so we directly link to the best financial data sources.
Financials
News
Core Scientific Targets AI Data Center Deals as Build Costs Climb
Key Points
- Interested in Core Scientific, Inc.? Here are five stocks we like better.
- Core Scientific is expanding five new data center sites and has raised capital to pre-fund equity needs
EQB Q2 Earnings Call Highlights
Key Points
- Interested in EQB Inc.? Here are five stocks we like better.
- EQB is on the verge of a major transformation as it expects to close its PC Financial acquisition on July 1, which
Toronto Dominion Bank Q2 Earnings Call Highlights
Key Points
- Interested in Toronto Dominion Bank (The)? Here are five stocks we like better.
- TD Bank posted a strong fiscal Q2 2026, with adjusted EPS up 21% year over year and return on equity
Cogent Communications Sees Data Center Sale Easing Debt Fears, Reviving Capital Returns
Key Points
- Interested in Cogent Communications Holdings, Inc.? Here are five stocks we like better.
- Cogent Communications says its planned sale of 10 data centers to I Squared Capital for $225
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Key Points
- Interested in Aura Biosciences, Inc.? Here are five stocks we like better.
- Aura Biosciences is nearing completion of enrollment in its registrational CoMpass study of bel-sar for
Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case
Key Points
- Interested in Amazon.com, Inc.? Here are five stocks we like better.
- Amazon has retired its Rufus chatbot and launched Alexa for Shopping, a unified AI assistant combining product
Astera Labs Targets $10B AI Connectivity Opportunity as Scorpio X-Series Ramps
Key Points
- Interested in Astera Labs, Inc.? Here are five stocks we like better.
- Astera Labs said demand remains strong across its connectivity portfolio and expects growth to accelerate
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
Key Points
- Interested in IDEAYA Biosciences, Inc.? Here are five stocks we like better.
- Darovasertib plus crizotinib hit its primary endpoint in a registrational Phase II/III study for
Doman Building Materials Group Q1 Earnings Call Highlights
Doman Building Materials Group (TSE:DBM) reported lower first-quarter revenue as weaker pricing across key construction material categories offset steady shipment activity, while margins improved
Constellation Software Q1 Earnings Call Highlights
Constellation Software (TSE:CSU) executives used the company’s first-quarter conference call to discuss acquisition activity, margin pressures, artificial intelligence and the company’s approach to
CCL Industries Q1 Earnings Call Highlights
CCL Industries (TSE:CCL.A) reported modest first-quarter sales growth and nearly flat operating income, while management said demand remained generally stable despite inflation pressures and
Radiant Logistics Q3 Earnings Call Highlights
Radiant Logistics (NYSEAMERICAN:RLGT) reported higher net income for its fiscal third quarter ended March 31, 2026, while adjusted earnings measures declined from the prior-year period, as
OR Royalties Q1 Earnings Call Highlights
OR Royalties (NYSE:OR) reported a record first quarter of 2026, with President and CEO Jason Attew saying the company is “off to an impressive
MDxHealth Q1 Earnings Call Highlights
MDxHealth (NASDAQ:MDXH) reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas
Eos Energy Enterprises Q1 Earnings Call Highlights
Eos Energy Enterprises (NASDAQ:EOSE) reported a sharp year-over-year increase in first-quarter revenue and outlined a new project financing
Humacyte Q1 Earnings Call Highlights
Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its
Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?
Rocket Lab (NASDAQ: RKLB) just had one of the most extraordinary weeks ever in its history as a public company. The stock closed at a new all-time high of $117.35 on Tuesday, having surged over
Uniti Group Q1 Earnings Call Highlights
Uniti Group (NASDAQ:UNIT) executives said the company started 2026 with stronger fiber growth, record Kinetic customer activity and continued demand from hyperscale customers tied to artificial
Sharplink Gaming Q1 Earnings Call Highlights
Sharplink Gaming (NASDAQ:SBET) reported a sharp increase in first-quarter revenue as management emphasized its Ethereum treasury strategy, while the
Ginkgo Bioworks Q1 Earnings Call Highlights
Ginkgo Bioworks (NYSE:DNA) said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn
Outset Medical Q1 Earnings Call Highlights
Outset Medical (NASDAQ:OM) reported first-quarter 2026 revenue of $27.9 million, as management pointed to “consistent execution” in console
5 Stocks Leading the Market's Rebound: The AI Connectivity Trade
While the broader market has spent much of 2026 fighting through a correction and uncertainty, a handful of stocks have not only held their ground but delivered extraordinary year-to-date (YTD)
Blue Owl’s Risk/Reward Profile Is Almost Too Good to Be True
Blue Owl Capital Inc. (NYSE: OWL), an alternative investment asset management group, has been making headlines for all the wrong reasons lately.
Shares are currently trading around $9, down
Rocket Lab’s Neutron Hiccup Sparked a Sell-Off—Overreaction or Omen?
Shares of Rocket Lab Corporation (NASDAQ: RKLB), one of the fastest-growing names in the aerospace and defense space, have come under pressure recently. The stock is down nearly 10% for the month
GE Vernova’s Q4 Was Strong—But the Backlog Number Matters More
Power and electrification company GE Vernova (NYSE: GEV) was a standout performer in 2025, delivering a total return of approximately 99%.
Shares are already up by almost 10% in 2026, buoyed by

